DEFEAT-COVID Trial

@ISARIC1 @FinancialTimes Amazing improvement. We hope that with positive results from drug trials like ours, @CovidTrial - looking to see if leflunomide, a drug used in rheumatoid arthritis improves outcomes, helps the survival rate get even better.

“The global survival rate for people hospitalised with #Covid19 has increased from 66 per cent in March to 84 per cent in August, according to the International Severe Acute Respiratory and Emerging Infection Consortium.” Read: on.ft.com/33Ahwmz @FinancialTimes #research

@LSHTM @PHE_uk At Ashford and St Peters Hospital NHS Trust, were doing our bit by running a new drug trial in medium to critical COVID patients who are hospitalised. We are looking to open new sites so contact megan.mcgee@nhs.net or kieran.brack1@nhs.net for info @CovidTrial

Calling all #PublicHealth and healthcare professionals 📢 What is your assessment of current and future #COVID19 interventions? 🤔 Take part in the UK Public Health Rapid Support Team's survey and help inform the pandemic response. 👉 bit.ly/2IUV67I @PHE_uk

Welcome to the DEFEAT-COVID clinical trial. We are trying to establish if leflunomide, used for rheumatoid arthritis, is clinically effective against COVID infection. We are looking to open new sites; contact megan.mcgee@nhs.net or kieran.brack1@nhs.net for info.